Skip to main content

THERMO FISHER SCIENTIFIC INC

For the period ended Sep 28, 2024. Filed Nov 1, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 28, 2024 · Filed Nov 1, 2024

TMO$694.76+2.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Non-GAAP Measures

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior periods.

We report adjusted operating income, adjusted operating margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:

Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.

Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not indicative of our normal operating costs.

Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.

The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.

We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.

The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.

Three months endedNine months ended
September 28,September 30,September 28,September 30,
(Dollars in millions except per share amounts)2024202320242023
Reconciliation of adjusted operating income
GAAP operating income$1,838$1,864$5,321$5,005
Cost of revenues adjustments (a)9142573
Selling, general and administrative expenses adjustments (b)2114(24)28
Restructuring and other costs (c)4584151379
Amortization of acquisition-related intangible assets4505841,5141,775
Adjusted operating income (non-GAAP measure)$2,362$2,560$6,987$7,260
Reconciliation of adjusted operating income margin
GAAP operating income margin17.3%17.6%16.9%15.7%
Cost of revenues adjustments (a)0.1%0.1%0.1%0.2%
Selling, general and administrative expenses adjustments (b)0.2%0.1%(0.1)%0.1%
Restructuring and other costs (c)0.4%0.8%0.5%1.2%
Amortization of acquisition-related intangible assets4.2%5.6%4.8%5.5%
Adjusted operating income margin (non-GAAP measure)22.3%24.2%22.2%22.7%
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense)$(16)$14$(2)$(32)
Adjustments (d)3(9)(8)36
Adjusted other income/(expense) (non-GAAP measure)$(13)$5$(10)$4
Reconciliation of adjusted tax rate
GAAP tax rate5.7%3.0%10.0%3.3%
Adjustments (e)4.8%7.0%0.3%6.7%
Adjusted tax rate (non-GAAP measure)10.5%10.0%10.3%10.0%
Three months endedNine months ended
September 28,September 30,September 28,September 30,
(Dollars in millions except per share amounts)2024202320242023
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc.$4.25$4.42$11.75$11.25
Cost of revenues adjustments (a)0.020.040.070.19
Selling, general and administrative expenses adjustments (b)0.050.03(0.06)0.07
Restructuring and other costs (c)0.120.220.390.98
Amortization of acquisition-related intangible assets1.171.503.954.57
Other income/expense adjustments (d)0.01(0.02)(0.02)0.09
Provision for income taxes adjustments (e)(0.36)(0.49)(0.50)(1.38)
Equity in earnings/losses of unconsolidated entities0.040.040.200.15
Noncontrolling interests adjustments (f)(0.02)(0.05)(0.02)(0.05)
Adjusted EPS (non-GAAP measure)$5.28$5.69$15.76$15.87
Reconciliation of free cash flow
GAAP net cash provided by operating activities$2,167$2,414$5,377$4,683
Purchases of property, plant and equipment(271)(332)(920)(1,074)
Proceeds from sale of property, plant and equipment20664076
Free cash flow (non-GAAP measure)$1,915$2,148$4,498$3,685

(a) Adjusted results exclude accelerated depreciation on fixed assets to be abandoned due to facility consolidations, charges for the sale of inventory revalued at the date of acquisition, and charges for inventory write-downs associated with large-scale abandonment of product lines.

(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation. Adjusted results in the third quarter of 2024 also exclude $5 million of accelerated depreciation on fixed assets to be abandoned due to facility consolidations.

(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, abandoned facilities, net gains on the sale of real estate, and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 million of contract termination costs associated with facility closures.

(d) Adjusted results exclude net gains/losses on investments.

(e) Adjusted results in exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements.

(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.

Critical Accounting Policies and Estimates

Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2023 describe the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s critical accounting policies during the first nine months of 2024.

Recent Accounting Pronouncements

A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.